
|Videos|July 2, 2013
Episode 14 - Concerns about Rising Costs of Treatment
Advertisement
Episodes in this series

During this segment, the panelists discuss their concerns about the rising costs of drugs currently available to treat multiple sclerosis (MS).
Gary M. Owens, MD, states that it is unclear why drug prices continue to rise, especially when certain options have been available for years. Dr Owens further explains there is no single formula to determine a return on investment for newer agents.
Because the drugs to treat MS are extremely expensive and difficult for patients to afford, Dr Owens and Leslie Fish, PharmD, suggest that when reviewing and negotiating the price of a therapy option, there is a need for transparency and comparative effectiveness.
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
3
Real-World Brexu-cel Results in MCL Mirror Trials; Cost, QOL Data Lag
4
Four Ways to Boost Awareness, Access for COVID-19 PEP
5

















